BioCorRx Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand how BioCorRx performed this year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment goals.

1. What does this company do?

BioCorRx focuses on addiction and weight loss. They offer programs that combine therapy, mobile app support, and medication. Their pharmaceutical division is seeking FDA approval for BICX104, an implantable pellet to treat alcohol and opioid addiction. They also hold the U.S. rights to Lucemyra, an FDA-approved drug for opioid withdrawal, which serves as their primary source of immediate revenue.

2. Financial Performance & Health

The company is currently in "survival mode," relying on outside funding to keep operations running.

• The Dilution Problem: To fund research, the company has issued millions of new shares. This process, called dilution, reduces your ownership percentage in the company. Even if the company eventually makes a profit, this increase in shares can make it harder for the value of your individual shares to grow.
• Cash Flow: While they received over $2.4 million in grant money in 2025, they are spending cash faster than they earn it. They are essentially trading future ownership (stock) for the cash they need to cover their monthly bills.
• Market Value: As of mid-2025, the company’s total market value was about $2.86 million, with shares trading at $0.35. This makes it a "micro-cap" stock, which is typically very volatile and harder to buy or sell quickly.

3. Major Wins and Challenges

• The Wins: They secured an $11 million grant from the National Institutes of Health (NIH) to study their BICX104 implant for methamphetamine addiction. This provides non-dilutive capital, meaning it funds operations without requiring them to issue more stock. They also added Lucemyra to their portfolio to generate revenue while they wait for their other drugs to clear regulations.
• The Hurdle: The company is not yet profitable. They have complex royalty agreements that require them to pay a portion of their sales to early investors and board members. This means that even if sales grow, a significant portion of that revenue is already committed to these obligations rather than being reinvested into the business.

4. Key Risks

The biggest risk is financial instability. They frequently sell new shares to stay afloat, and this constant supply of new stock hitting the market often creates downward pressure on the share price. Furthermore, their success depends entirely on FDA approvals. Clinical trials are expensive, and if a drug fails to meet its goals, the investment in that drug could be lost entirely.

5. Future Outlook

BioCorRx is betting its future on its drug pipeline and Lucemyra. They are using Lucemyra sales to build a foundation for the eventual launch of BICX104. Until the business earns more cash than it spends, it remains a high-risk, speculative investment that relies on outside funding to survive.

Final Thought for Investors: When considering an investment in a micro-cap company like BioCorRx, ask yourself if you are comfortable with the high level of risk associated with clinical-stage pharmaceutical companies. Because the company is currently dependent on selling shares to fund its operations, your primary focus should be on their ability to reach profitability or secure non-dilutive funding (like grants) before their cash reserves run low.